| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6217895 | ALIMERA SCIENCES INC | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) | |
| US6548078 | ALIMERA SCIENCES INC | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) | |
| US8252307 | ALIMERA SCIENCES INC | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Jun, 2019
(4 years ago) | |
| US6375972 | ALIMERA SCIENCES INC | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(4 years ago) | |
| US8871241 | ALIMERA SCIENCES INC | Injectable sustained release delivery devices |
Aug, 2027
(3 years from now) | |
Iluvien is owned by Alimera Sciences Inc.
Iluvien contains Fluocinolone Acetonide.
Iluvien has a total of 5 drug patents out of which 4 drug patents have expired.
Expired drug patents of Iluvien are:
- US6217895
- US6548078
- US8252307
- US6375972
Iluvien was authorised for market use on 26 September, 2014.
Iluvien is available in implant;intravitreal dosage forms.
Iluvien can be used as treatment of diabetic macular edema.
The generics of Iluvien are possible to be released after 12 August, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 26, 2017 |
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 26 September, 2014
Treatment: Treatment of diabetic macular edema
Dosage: IMPLANT;INTRAVITREAL
More Information on Dosage
ILUVIEN family patents
